课题基金 / 基金详情

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract Solid tumors cannot grow beyond a few millimeters in size without the support of co-opted stromal cells. The function of different stromal cells in the tumor microenvironment may be subverted in ways that are beneficial for tumor progression. Examples are the tumor-induced and specific polarization of immune/inflammatory cells, conversion of fibroblasts into tumor-supportive myofibroblasts, and dysfunctional tumor endothelial cells. Irregular and hyper-permeable vasculature occurs early when only a few hundred-tumor cells are present. Leaky tumor blood vessels deposit fibrin in a perivascular niche that forms scaffolds for tumor cell growth and invasion as well as sparks angiogenesis. Using a miRNA screen of freshly isolated TECs, I identified a TGFβ-regulated miRNA (miR-30c) that controls vascular-directed fibrinolysis in tumors. miR-30c is increased in TECs relative to normal endothelial cells (NECs) whereas its target PAI-1 (a fibrinolysis inhibitor) is strikingly decreased. TECs secrete less PAI-1 and they rapidly degrade fibrin scaffolds resulting in aberrant in vitro sprouting. However, TGFβ and miR-30c antagomiRs reduce miR-30c expression which re-instates PAI-1 secretion, diminishes fibrinolysis, and “normalizes” TEC sprouting in vitro. miR-30c antagomiRs coupled to vascular-tropic nanoparticles enforce vascular-specific PAI-1 expression and strikingly promote robust orthotopic mammary tumor growth in vivo. Thus, manipulation of vascular-specific expression of miR-30c in tumors promotes tumor growth likely due to enhanced fibrin-mediated angiogenesis. I propose an axis between TGFβ, miR-30c and PAI-1 in TECs controls the rate of perivascular fibrinolysis and is therefore an important effector of tumor angiogenesis and progression.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
分化肌细胞脱细胞ECM-cells sheet 3D 支架构建及其促进容积性肌组织缺损再 生修复应用及机制研究
CAFs-TAMs-tumor cells调控在HRHPV感染致癌中的作用机制研究及AI可追溯预测模型建立
  • 批准号:
    82072862
  • 项目类别:
    面上项目
  • 资助金额:
    56.0万元
  • 批准年份:
    2020
  • 负责人:
    徐云升
  • 依托单位:
S100A8/A9--Myeloid cells特异性可溶性表氧化物水解酶(sEH)基因敲除改善胰岛素抵抗的新靶点
  • 批准号:
    82070825
  • 项目类别:
    面上项目
  • 资助金额:
    53.0万元
  • 批准年份:
    2020
  • 负责人:
    徐西振
  • 依托单位:
Leader cells通过CCL5调控糖酵解及基质硬度促进结直肠癌集体侵袭的 作用机制
  • 批准号:
    81903002
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.5万元
  • 批准年份:
    2019
  • 负责人:
    王斐斐
  • 依托单位: